Abstract

Understanding the dynamics of ligands bound to proteins is an important task in medicinal chemistry and drug design. However, the dominant technique for determining protein-ligand structures, X-ray crystallography, does not fully account for dynamics and cannot accurately describe the movements of ligands in protein binding sites. In this article, an alternative method, ensemble refinement, is used on six protein-ligand complexes with the aim of understanding the conformational diversity of ligands in protein crystal structures. The results show that ensemble refinement sometimes indicates that the flexibility of parts of the ligand and some protein side chains is larger than that which can be described by a single conformation and atomic displacement parameters. However, since the electron-density maps are comparable and Rfree values are slightly increased, the original crystal structure is still a better model from a statistical point of view. On the other hand, it is shown that molecular-dynamics simulations and automatic generation of alternative conformations in crystallographic refinement confirm that the flexibility of these groups is larger than is observed in standard refinement. Moreover, the flexible groups in ensemble refinement coincide with groups that give high atomic displacement parameters or non-unity occupancy if optimized in standard refinement. Therefore, the conformational diversity indicated by ensemble refinement seems to be qualitatively correct, indicating that ensemble refinement can be an important complement to standard crystallographic refinement as a tool to discover which parts of crystal structures may show extensive flexibility and therefore are poorly described by a single conformation. However, the diversity of the ensembles is often exaggerated (probably partly owing to the rather poor force field employed) and the ensembles should not be trusted in detail.

Highlights

  • An important goal of medicinal chemistry is to design new synthetic ligands that bind to a specific protein involved in a given disease, modulating its action

  • We have performed ensemble refinement (ER) for six galectin-3C–ligand complexes and compared the results with those obtained with standard crystallographic refinement (SR; i.e. the original deposited crystal structures), qFit-ligand refinement and MD simulations in both solvent and in the crystals

  • The present study has shown that ER sometimes gives a ligands, indicating conformational diversity of parts of the qualitatively different picture of ligands binding to a protein to ligands that is larger than that indicated by the ADPs in the standard refinement

Read more

Summary

Introduction

An important goal of medicinal chemistry is to design new synthetic ligands that bind to a specific protein involved in a given disease, modulating its action. Due to recent technological advances, structure-based drug design has become standard in drug design, but several parts of it, for example estimating the flexibility of the ligand, as well as the entropy and free energy of binding, remain challenging (Wang et al, 2018; Parks et al, 2020) This is because protein–ligand binding is a complex process that is governed by specific molecular interaction between a ligand and a protein and by changes in the atomic dynamics exhibited by the ligand and the protein (Gohlke & Klebe, 2002; Zhou & Gilson, 2009; Verteramo et al, 2019; Klebe, 2019). Recent software packages can build alternate conformations automatically (Keedy et al, 2015), this has not yet become standard practice

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call